Laboratorios Farmaceuticos Rovi, S.A.

ROVI

ES0157261019

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 10:35:25 2024-04-25 am EDT			5-day change	1st Jan Change
85.08 ^EUR	+6.88%		+7.74%	+42.19%

Apr. 02	Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment	MT
Mar. 12	Rovi, Partners to Form Entity for Advanced Therapies R&D	MT

Laboratorios Farmaceuticos Rovi, S.A.(BME:ROVI) added to Madrid Ibex 35 Index

December 22, 2021 at 12:00 am EST

Laboratorios Farmaceuticos Rovi, S.A. has been added to Madrid Ibex 35 Index.

Latest news about Laboratorios Farmaceuticos Rovi, S.A.

Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment	Apr. 02	MT
Rovi, Partners to Form Entity for Advanced Therapies R&D	Mar. 12	MT
Rovi explores sale of unit that makes drugs for third parties	Mar. 07	RE
Rovi Responds to Press Speculation Regarding Contract Development Business Deal	Mar. 07	MT
Transcript : Laboratorios Farmaceuticos Rovi, S.A., 2023 Earnings Call, Feb 27, 2024	Feb. 27
The Ibex-35 opts for caution as corporate results continue to trickle in.	Feb. 27	RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 25	CI
US FDA finds control lapses at Moderna manufacturing plant	Dec. 15	RE
Italy, Spain stocks hit peaks after over 20% rally in 2023	Nov. 30	RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 08	CI
Transcript : Laboratorios Farmaceuticos Rovi, S.A., H1 2023 Earnings Call, Jul 26, 2023	23-07-26
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-26	CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.	23-07-26	CI
Global markets live: Macy's, Salesforce, Dollar General, Nordstrom, Exxon...	23-06-01
Rovi denies being investigated for alleged public subsidies	23-06-01	RE
Laboratorios Farmaceuticos Rovi Denies Receiving Unlawful Public Grants	23-05-31	MT
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.	23-04-14	CI
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-14	CI
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-21	CI
Laboratorios Farmaceuticos Rovi, S.A. Proposes Dividend for the Year 2022	23-02-21	CI
Transcript : Laboratorios Farmaceuticos Rovi, S.A., 2022 Earnings Call, Feb 21, 2023	23-02-21
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.	23-02-20	CI
ROVI Submits Final Responses to US FDA over Risvan Marketing Authorization Application	23-02-16	MT
Transcript : Laboratorios Farmaceuticos Rovi, S.A. - Analyst/Investor Day	22-11-23
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.	22-11-04	CI

Chart Laboratorios Farmaceuticos Rovi, S.A.

Duration

Period

Chart Laboratorios Farmaceuticos Rovi, S.A.

More charts

Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - pharmaceutical products manufactured under contract (49%); - prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%). Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

IBEX 35

More about the company

Income Statement Evolution

More financial data

Ratings for Laboratorios Farmaceuticos Rovi, S.A.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

79.6 EUR

Average target price

79.18 EUR

Spread / Average Target

-0.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LABORATORIOS FARMACEUTICOS ROVI, S.A.	+42.19%	4.41B
NOVO NORDISK A/S	+24.35%	562B
JOHNSON & JOHNSON	-6.44%	358B
MERCK & CO., INC.	+19.33%	322B
ABBVIE INC.	+7.49%	297B
ASTRAZENECA PLC	+13.40%	219B
NOVARTIS AG	+6.03%	199B
ROCHE HOLDING AG	-10.43%	196B
PFIZER, INC.	-10.96%	149B
AMGEN INC.	-6.90%	146B

Other Pharmaceuticals